Initial results of a clinical trial of Fluosol-DA 20 percent in acute cerebral ischemia.

Abstract

We present three patients in whom Fluosol-DA 20 percent was administered in the presence of ischemic cerebral vascular disease. While transient improvement observed in two cases may have been related to Fluosol-DA administration it is premature to use these results to comment on the potential protective or therapeutic efficacy of Fluosol-DA in ischemic cerebral vascular disease. One patient progressively deteriorated neurologically during and after the infusion. Our initial impressions are limited to the observations that Fluosol-DA in doses of 20 ml/kg can be administered easily and without major effects on hemodynamic or pulmonary function. One patient had a transient leukopenia.

• Authors: K W Swann, A H Ropper, N T Zervas
• Journal: Progress in clinical and biological research (Prog Clin Biol Res) Vol. 122 Pg. 399-404 ( 1983) ISSN: 0361-7742 [Print] United States
• PMID: 6348787 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Blood Substitutes
• Drug Combinations
• Fluorocarbons
• Hydroxyethyl Starch Derivatives
• glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination

Topics

• Acute Disease
• Adult
• Blood Pressure (drug effects)
• Blood Substitutes (therapeutic use)
• Brain Ischemia (drug therapy)
• Clinical Trials as Topic
• Drug Combinations (therapeutic use)
• Female
• Fluorocarbons (therapeutic use)
• Humans
• Hydroxyethyl Starch Derivatives
• Male
• Middle Aged